Sellas Prices $150M Offering at $13, a 28% Discount to Tuesday's Close
SLS has more than doubled off its 52-week low of $1.39 on elevated volume (3.9× avg).
Summary
Sellas priced its $150M underwritten offering at $13.00 a share for 11,538,462 shares, a steep discount to the $17.98 last price. Underwriters have an option to buy 1.7M additional shares, and the company expects the offering to close Nov. 20. The raise follows Tuesday's 156% surge after the Phase 3 REGAL trial of galinpepimut-S met its primary overall survival endpoint, and it comes despite the company reporting $134.7M in cash at Q3, enough for at least twelve months. The discount reflects underwriters pricing in the post-spike volatility and the size of the deal relative to the float. The offering was launched Nov 17 with a 30-day option for up to $22.5M more; pricing at $13 is the key term traders now have.
At the time of this announcement, SLS was trading at $17.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $1.39 to $24.89. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.